X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7) 7
index medicus (7) 7
cancer (6) 6
middle aged (6) 6
hematology (5) 5
adult (4) 4
aged (4) 4
chemotherapy (4) 4
diagnosis (4) 4
female (4) 4
survival (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
care and treatment (3) 3
cytarabine (3) 3
disease (3) 3
dosage and administration (3) 3
guidelines (3) 3
male (3) 3
methotrexate (3) 3
non-hodgkins-lymphoma (3) 3
prognosis (3) 3
analysis (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
chronic lymphocytic leukemia (2) 2
combined modality therapy (2) 2
cytarabine - adverse effects (2) 2
diagnostic imaging (2) 2
disease-free survival (2) 2
drug administration schedule (2) 2
follow-up studies (2) 2
gene expression (2) 2
kaplan-meier estimate (2) 2
leukemia, lymphocytic, chronic, b-cell - diagnosis (2) 2
leukemia, lymphocytic, chronic, b-cell - diagnostic imaging (2) 2
leukemia, lymphocytic, chronic, b-cell - genetics (2) 2
leukemia, lymphocytic, chronic, b-cell - pathology (2) 2
lymphomas (2) 2
methotrexate - adverse effects (2) 2
methotrexate - therapeutic use (2) 2
monoclonal antibodies (2) 2
neoplasm staging (2) 2
non-hodgkin's lymphomas (2) 2
oncology, experimental (2) 2
patients (2) 2
progression (2) 2
prospective studies (2) 2
research (2) 2
response criteria (2) 2
stem cells (2) 2
tomography (2) 2
tomography, x-ray computed (2) 2
transplantation (2) 2
treatment outcome (2) 2
young adult (2) 2
1st-line treatment (1) 1
abdomen (1) 1
abdominal ct scan (1) 1
abridged index medicus (1) 1
adolescent (1) 1
adp-ribosyl cyclase 1 - blood (1) 1
adp-ribosyl cyclase 1 - genetics (1) 1
age (1) 1
antibodies, monoclonal, murine-derived - administration & dosage (1) 1
antibodies, monoclonal, murine-derived - adverse effects (1) 1
antimetabolites, antineoplastic - adverse effects (1) 1
antimetabolites, antineoplastic - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
article (1) 1
autografts (1) 1
b cells (1) 1
b-cell lymphoma (1) 1
b-lymphocytes - metabolism (1) 1
b-lymphocytes - pathology (1) 1
beta 2-microglobulin - blood (1) 1
beta 2-microglobulin - genetics (1) 1
beta-2-microglobulin (1) 1
binet stage (1) 1
blood (1) 1
body regions (1) 1
bortezomib (1) 1
brain - drug effects (1) 1
brain - radiation effects (1) 1
breast cancer (1) 1
cd38 antigen (1) 1
cells (1) 1
central nervous system diseases (1) 1
central nervous system neoplasms - drug therapy (1) 1
central nervous system neoplasms - immunology (1) 1
central nervous system neoplasms - mortality (1) 1
central nervous system neoplasms - radiotherapy (1) 1
central nervous system neoplasms - surgery (1) 1
central nervous system neoplasms - therapy (1) 1
central-nervous-system (1) 1
cerebrospinal-fluid (1) 1
chromosome aberrations (1) 1
chromosomes, human, pair 12 - genetics (1) 1
chronic lymphatic leukemia (1) 1
clinical monoclonal b-cell lymphocytosis (1) 1
clinical monoclonal b‐cell lymphocytosis (1) 1
clinical trials (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9700, pp. 1512 - 1520
Summary Background Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy... 
Internal Medicine | DEFERRED RADIOTHERAPY | MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | INTERNATIONAL WORKSHOP | RESPONSE CRITERIA | EUROPEAN ORGANIZATION | CONSOLIDATING RADIOTHERAPY | NON-HODGKINS-LYMPHOMA | INITIAL TREATMENT | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Lymphoma, Non-Hodgkin - radiotherapy | Cranial Irradiation - methods | Central Nervous System Neoplasms - radiotherapy | Adult | Lymphoma, Non-Hodgkin - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Combined Modality Therapy | Remission Induction | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Cytarabine | Patient outcomes | Central nervous system diseases | Dosage and administration | Lymphomas | Drug therapy, Combination | Methotrexate | Drug therapy | Data analysis | Disease | Monoclonal antibodies | Data collection | Radiation therapy | Patients | Tropical diseases | Index Medicus | Abridged Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2015, Volume 10, Issue 3, p. e0118801
Journal Article
British Journal of Haematology, ISSN 0007-1048, 02/2012, Volume 156, Issue 3, pp. 346 - 353
Summary This study investigated the clinical activity and toxicity of R‐HCVAD‐AM [rituximab plus HyperCVAD (R‐HCVAD) alternating with high‐dose cytarabine and... 
non‐Hodgkin lymphoma | clinical trials | prognostic factors | chemotherapy | monoclonal antibodies | Non-Hodgkin lymphoma | Clinical trials | Monoclonal antibodies | Chemotherapy | Prognostic factors | IMMUNOCHEMOTHERAPY | PROGRESSION-FREE SURVIVAL | SEQUENTIAL CHEMOTHERAPY | CVAD | non-Hodgkin lymphoma | REGIMENS | TRANSPLANTATION | THERAPY | RESCUE | UPDATE | HEMATOLOGY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Infection - etiology | Young Adult | Vincristine - administration & dosage | Adult | Lymphoma, Mantle-Cell - genetics | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Dexamethasone - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Genetic Markers | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Methotrexate - administration & dosage | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Care and treatment | Stem cells | Dosage and administration | Transplantation | Non-Hodgkin's lymphomas | Methotrexate | Cancer | Autografts | cytarabine | Toxicity | mantle cell lymphoma | Survival | Age | rituximab | Index Medicus
Journal Article
The Lancet Haematology, ISSN 2352-3026, 11/2017, Volume 4, Issue 11, pp. e510 - e523
Journal Article
American Journal of Hematology, ISSN 0361-8609, 07/2013, Volume 88, Issue 7, pp. 539 - 544
Journal Article
European Journal of Haematology, ISSN 0902-4441, 01/2016, Volume 96, Issue 1, pp. 36 - 45
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.